Compare
Green Planet Bio Engineering Co. Ltd. vs Vaxart, Inc. vs Amgen Inc vs CEL SCI Corp
| Latest fiscal year | Green Planet Bio Engineering Co. Ltd. GPLB | Vaxart, Inc. VXRT | Amgen Inc AMGN | CEL SCI Corp CVM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-09-30 |
| Revenue | n/a | $237.26M | $36.75B | n/a |
| Revenue growth (YoY) | n/a | +726.7% | +10.0% | n/a |
| Gross margin | n/a | n/a | 67.2% (computed) | n/a |
| Operating margin | n/a | 7.6% | 24.7% | n/a |
| Net margin | n/a | 6.9% | 21.0% | n/a |
| Net income | -$35.8K | $16.33M | $7.71B | -$25.41M |
| EPS (Diluted) | $0.00 | $0.07 | $14.23 | -$6.27 |
| Operating cash flow | -$36.5K | $7.71M | $9.96B | -$17.12M |
| Free cash flow | n/a | $7.57M | $8.10B | -$17.16M |
| Cash & equivalents | n/a | n/a | $9.13B | n/a |
| Total assets | n/a | $186.08M | $90.59B | $28.16M |
| Total liabilities | n/a | $98.28M | n/a | $12.20M |
| Shareholders' equity | -$501.0K | $87.80M | $8.66B | $15.96M |
| Return on year-end equity | n/a | 18.6% | 89.1% | -159.2% |
| Shares outstanding | 20.01M | 240.49M | 538.80M | 8.02M |
Revenue, most recent five fiscal years
| Fiscal year | Green Planet Bio Engineering Co. Ltd. | Vaxart, Inc. | Amgen Inc | CEL SCI Corp |
|---|---|---|---|---|
| Latest | n/a | $237.26M Ended 2025-12-31 | $36.75B Ended 2025-12-31 | $264.0K Ended 2014-09-30 |
| 1 year earlier | n/a | $28.70M Ended 2024-12-31 | $33.42B Ended 2024-12-31 | $159.6K Ended 2013-09-30 |
| 2 years earlier | n/a | $7.38M Ended 2023-12-31 | $28.19B Ended 2023-12-31 | $254.6K Ended 2012-09-30 |
| 3 years earlier | n/a | $107.0K Ended 2022-12-31 | $26.32B Ended 2022-12-31 | $956.2K Ended 2011-09-30 |
| 4 years earlier | n/a | $892.0K Ended 2021-12-31 | $25.98B Ended 2021-12-31 | n/a |